NAD Repletion Therapy: A Silver Bullet for HFpEF?
- 27 May 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 128 (11) , 1642-1645
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenScience, 2021
- NAD + Repletion Reverses Heart Failure With Preserved Ejection FractionCirculation Research, 2021
- Nicotinamide for the treatment of heart failure with preserved ejection fractionScience Translational Medicine, 2021
- Extreme Acetylation of the Cardiac Mitochondrial Proteome Does Not Promote Heart FailureCirculation Research, 2020
- Cardiac Rehabilitation Increases SIRT1 Activity and β-Hydroxybutyrate Levels and Decreases Oxidative Stress in Patients with HF with Preserved Ejection FractionOxidative Medicine and Cellular Longevity, 2019
- Female Sex Is Protective in a Preclinical Model of Heart Failure With Preserved Ejection FractionCirculation, 2019
- Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory SignaturesCell Reports, 2019
- Nitrosative stress drives heart failure with preserved ejection fractionNature, 2019
- Normalization of NAD + Redox Balance as a Therapy for Heart FailureCirculation, 2016
- AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activityNature, 2009